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Short Communication
Polymorphisms in the Bradykinin B2 Receptor Gene and
Childhood Asthma
suspected to be involved in lung disease (Nadar et al.,
1996). In contrast to B2 receptors, however, there is no
evidence for a functional role of B1 receptors in the
pathogenesis of asthma so far.
Since childhood asthma is strongly associated with a
positive family history of asthma and atopic disease
(Frischer et al., 1993), a genetic background has long
been suspected. Segregation studies have resulted in a
polygenetic model of inheritance (Schork, 1997) and
genome-wide linkage studies have – among others –
identified polymorphic markers on chromosome 14q to
be associated with asthma (Ober et al., 2000). Among
other candidate genes for an association with asthma,
such as those for the mast cell chymase, for NFkB1 and
for parts of the T cell receptor, both the B1- and the B2-
BKR gene have been localized on chromosome 14q
(Kammerer et al., 1995).
Earlier reports from our group have described polymor-
phisms in the three exons of the B2 receptor gene, sug-
gesting that they may be relevant for bradykinin-associat-
ed diseases (Braun et al., 1995). In exon 1, a tandem
repeat polymorphism affecting the gene’s transcription
rate, has been identified. Among the 3 common alleles
(2G, 3T and 3G), the 2G allele was associated with the
highest and the 3T allele with the lowest transcription rate.
In exon 2, a C to T transition was found which results in an
arginine to cysteine substitution (R14C), thereby potential-
ly influencing the receptor’s affinity and stability. In exon 3,
a more complex tandem repeat polymorphism with two
common alleles, containing 43 and 33 repeat units, re-
spectively, and two rare variants were identified. Situated
in the non-coding 3´-region of exon 3, this polymorphism
might affect the stability of the mRNA (Braun et al., 1996).
Clinical association studies have demonstrated an as-
sociation between the B2-BKR exon 1 polymorphism
and the clinical manifestation of angioedema in C1-es-
terase inhibitor deficiency (Lung et al., 1997). Studies of
the B2-BKR exon 2 polymorphism in patients with end
stage renal disease have so far produced conflicting re-
sults (Bachvarov et al., 1998; Zychma et al., 1999).
We have studied the polymorphisms in the three exons
of the B2-BKR gene in 77 asthmatics and 73 controls
from the University Children’s Hospital in Munich, Ger-
many. In order to eliminate ethnic confounding, the re-
spective German subgroups (64 asthmatics, 56 controls)
were also compared. There was a slight difference in age
that was statistically significant (p=0.0487) in the German
subgroup, although median and range were the same as
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Bradykinin has been suggested as one of the key me-
diators of bronchial asthma. Polymorphisms with a
potential functional relevance have been described in
the B2 bradykinin receptor gene. Study of these poly-
morphisms in 77 children with asthma and 73 controls
revealed no association. However, when comparing
the asthmatics according to their age at onset (before
and after age 4), the exon 1 allele BE1-2G was signifi-
cantly associated with late-onset asthma (p<0.05).
Since BE1-2G has previously been shown to lead to a
higher transcription rate of the B2 receptor, this result
warrants further investigation of the role of bradykinin
in conferring susceptibility to pediatric asthma.
Key words: B2 /BKR/Single nucleotide polymorphism/
SNP. 
The nonapeptide bradykinin (BK) has been suggested as
one of the key mediators of bronchial asthma (Barnes,
1989). Elevated levels of bradykinin have been detected
in the airways of asthmatics (Christiansen et al., 1992)
and inhalation of bradykinin induces bronchoconstriction
in asthmatics, but not in healthy controls (Polosa and
Holgate, 1990). B2 bradykinin receptors (B2-BKR) on
smooth muscle cells (Mak and Barnes, 1991), C-fibers
(Fox et al., 1993), blood vessels (Ichinose and Barnes,
1990), mucous glands (Baraniuk et al., 1990) and en-
dothelial cells (Mak and Barnes, 1991) have been sug-
gested to mediate the effects of BK on bronchial con-
striction, edema formation and dyscrinism, respectively.
In a placebo-controlled, randomized clinical trial, the se-
lective B2-BKR-antagonist HOE 140 (Icatibant®) acted as
a potent anti-inflammatory drug in adult asthmatics (Ak-
bary et al., 1996). While B2 receptors are constitutively
expressed, B1 bradykinin-receptors are only induced in
pathological states of the lung, and have thus also been
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in the total sample (Table 1). As expected, we found sig-
nificant differences in the distribution of known risk fac-
tors for childhood asthma, namely allergic rhinitis
(p<0.0001) and a family history of allergic rhinitis and
atopic dermatitis (p<0.01, respectively). Atopic dermatitis
was also significantly associated with asthma in the total
sample (p<0.05). In the smaller German subgroup, the
difference was preserved in tendency (28% in asthmatics
versus 14% in controls), although not being significant
(p=0.08).
Genotype and allelic distributions were in accordance
with Hardy Weinberg equilibrium in all groups as tested
with the adapted c2 test (Mueller and Clerget-Darpoux,
1991) (data not shown) and showed no significant differ-
ences between asthmatics and controls for all three exon
polymorphisms (Table 2). Since there were no significant
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Table 1 Clinical Characteristics of Asthmatics and Controls.
Characteristics Asthmatics Controls Statistical analysis Statistical analysis
(n=77) (n=73) (whole group) (German group)
Age 9 (2 – 17) 8 (1 – 17) n.s.* p<0,05
Gender (female/male) 27 / 50 27 / 37 n.s. n.s.
Allergic rhinitis 25 (32%) 1 (1%) p<0.0001 p<0.0001
Atopic dermatitis 20 (26%) 8 (11%) p<0.05 n.s.
Family history of
allergic rhinitis 42 (55%) 23 (32%) p<0.01 p<0.05
Family history of
atopic dermatitis 42 (55%) 7 (10%) p<0.01 p<0.01
Family history of 
asthma 42 (55%) excluded not tested not tested
* n.s. = not significant.
Age is given as median (range) and the number and percentage of carriers are listed for each risk
factor. The age was compared using the Wilcoxon test, gender and risk factors were analyzed with
the exact Fisher test. The statistical analysis was done for the whole group and the German group,
respectively. Data were obtained through standardized questionnaires and informed consent was
given by at least one parent. Children with asthma, wheezing bronchitis, recurrent bronchitis or a
history of asthma and those with chronic disease or suspected or known inherited disease were ex-
cluded from the control group.
Table 2 Allelic Frequencies for the B2-BKR Gene in Asthmatics and Controls.
Allele Asthmatics Controls Exact Monte Carlo
(n=77) (n=73) Fisher test test
BE1-2G 0.533 0.500
BE1-3T 0.266 0.356 n.s.* n.s.
BE1-3G 0.201 0.144
BE2-C 0.916 0.925 n.s. n.s.
BE2-T 0.084 0.075
BE3-R43 0.851 0.863
BE3-R33 0.117 0.103 n.s. n.s.
BE3-var 0.032 0.034
*n.s.= not significant.
Allelic frequencies for polymorphisms in the three exons of the B2-BKR gene in
asthmatics and controls. The statistical analysis with the exact Fisher test for al-
lelic frequencies and the Monte Carlo test for associations between disease and
alleles at highly polymorphic loci (Sham and Curtis, 1995), used for the compari-
son of the respective genotype distributions, were not significant (n.s.) in the
whole group, the German group (64 asthmatics, 56 controls) and the ‘atopic’
group (69 atopic asthmatics, 73 controls).
The polymorphism in exon 1 was shown by single-strand conformational poly-
mophism (SSCP) analysis in a 10% polyacrylamide gel buffered with 0.5 x TBE.
Electrophoresis in 1 x TBE buffer at 120 V for 12 h produced additional heterodu-
plex bands for better differentiation of heterozygote carriers of 2G from homozy-
gous carriers of 3G and 3T compared with the conditions described previously.
The polymorphism in exon 2 was detected by gel electrophoresis after digestion
with restriction endonuclease TaqI and the exon 3 polymorphism by gel elec-
trophoresis directly, both as previously described (Braun et al., 1995).
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associations, genotype distributions and data for the re-
spective subgroups are not listed separately.
In order to account for potential pathogenetic differ-
ences, the asthma group was stratified into subgroups
with an onset of symptoms before (n=31, early onset
asthmatics) and after the age of 4 years (n=46, late onset
asthmatics). Risk factors were similar in both groups with
a non-significant trend towards a higher frequency of
atopic dermatitis in the early onset and of allergic rhinitis
in the late onset group. This may, however, be explained
by differences in the median age (10 versus 8 years).
There was also a slightly higher proportion of girls in the
late onset group, that was not statistically significant
(Table 3). Similar results were obtained in the German
group comparing 28 early-onset and 36 late-onset asth-
matics.
There was a significantly higher frequency of the exon
1 allele BE1-2G in the late onset group (p<0.05; Table 4).
In the smaller German group, this association did not
reach statistical significance (p=0.09), but the magnitude
of difference between the allelic frequencies remained al-
most the same (0.168 versus 0.190). The loss of signifi-
cance may thus be attributed to the reduced sample size
(28 early- and 36 late-onset asthmatics), rather than a
false positive association due to ethnical differences.
Apart from the allele BE1-2G, the statistical analyses
showed no significant association in the complete group
and in the German subgroup (Table 4).
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Table 3 Clinical Characteristics of Early and Late Onset Asthmatics.
Risk factor Early onset Late onset Statistical analysis
(n=31) (n=46) (Whole and German group)
Age 8 (2 – 15) 10 (4 – 17) n.s.*
Gender (girls/boys) 9 / 22 18 / 28 n.s.
Allergic rhinitis 8 (26%) 17 (37%) n.s.
Atopic dermatitis 10 (32%) 10 (22%) n.s.
Atopy (IgE>100 kU/l) 29 (94%) 40 (87%) n.s.
Family history of
asthma 19 (61%) 23 (50%) n.s.
Family history of 
allergic rhinitis 19 (61%) 23 (50%) n.s.
Family history of
atopic dermatitis 8 (26%) 14 (30%) n.s.
*n.s. = not significant.
Age, gender and risk factors for childhood asthma in early and late onset asthmatics. The
age is given as median (ranges). For the risk factors, the number and percentage of sub-
jects carrying the respective risk factor are listed. The age was compared using the Wilcox-
on test, gender and risk factors were analyzed with the exact Fisher test. The statistical
analysis was done for the whole group and the German group (28 early-onset and 36 late-
onset asthmatics), respectively.
Table 4 Allelic Frequencies for the B2-BKR Gene in Early and Late Onset Asthmatics.
Whole group German group
Early onset Late Exact Early onset Late Exact Monte
Alleles (n=31) onset Fisher (n=28) onset Fisher Carlo
(n=46) test (n=36) test test
BE1-2G 0.419 0.609 p = 0.034 0.429 0.597 n.s*
BE1-3T 0.306 0.239 n.s. 0.304 0.236 n.s. n.s.
BE1-3G 0.274 0.152 n.s. 0.268 0.166 n.s.
BE2-C 0.935 0.902 n.s. 0.929 0.889 n.s. n.s.
BE2-T 0.065 0.098 n.s. 0.071 0.111 n.s.
BE3-R43 0.903 0.815 n.s. 0.893 0.819 n.s.
BE3-R33 0.065 0.152 n.s. 0.071 0.167 n.s. n.s.
BE3-var 0.032 0.033 n.s. 0.036 0.014 n.s.
* n.s.= not significant.
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A number of diseases in childhood are associated with
wheezing, but are not necessarily asthma (Silverman,
1993) and the recruitment of non-asthmatic wheezers is a
potential pitfall for any study on pediatric asthma. In a large
prospective study following children from birth until the
age of 6 years, three major types of wheezing have been
identified: transient early wheezing occurring in infants un-
til the age of 3 years, persistent wheezing up to at least 6
years of age and late-onset wheezing starting after the age
of 3 years (Martinez et al., 1995). Only persistent and late
onset wheezing were associated with atopy, atopic der-
matitis, allergic rhinitis and maternal asthma. We tried to
eliminate transient early wheezers from our study group by
recruiting – with one exception – only patients over 4 years
of age. Recently, another type of persistent wheezers has
been described, with symptoms up to early school years,
that are usually not accompanied by atopy and bronchial
hyperresponsiveness, and do not progress to chronic
bronchial asthma (Martinez and Helms, 1998). The fact
that 90% of our patients were atopic may thus indicate
that we have not recruited a major proportion of these pa-
tients, although it cannot be excluded with certainty.
As the control group was recruited from our general
pediatric clinic, a selection bias towards children with
premorbidities needed to be considered. We have tried to
minimize this potential bias by excluding all children with
chronic disease and with suspected or known inherited
disease. We have also excluded all children with a family
history of asthma from the control group, but some had a
family history of allergic rhinitis (30%) or atopic dermatitis
(10%) and a few children were suffering from one or both
of these diseases (Table 1). An atopic disposition may
thus have been present in a part of our control group, al-
though this did not exceed the proportion in the general
population. Additionally, since we have attempted to
study genetic markers for asthma and not for atopy, this
should not necessarily have affected our results. 
Because the distribution of the B2 receptor polymor-
phisms depends on ethnicity (Lung et al., 1997), we have
only recruited Caucasians in the study and have sepa-
rately compared the respective German groups to rule
out ethnical confounding. We have observed a loss of
significance for atopic dermatitis and for the association
of late onset asthma with the allele 2G in the German
groups. However, this is most likely due to reduced num-
bers and can hardly be attributed to ethnic differences.
Different pathogenetic models have been associated
with the age of onset in pediatric asthma (Martinez and
Helms, 1998). Interestingly, we found an association of
late-onset asthma with the exon 1 allele 2G, which had
earlier been associated with a relatively increased tran-
scription rate of the B2 receptor (Braun et al., 1996). This
is consistent with the hypothesis that bradykinin may be
more important in the pathogenesis of late onset than of
early onset asthma. However, larger studies will be nec-
essary to reproduce and specify this association. 
Since the exon 1 polymorphism is associated with the
transcription rate of the B2 receptor gene, it is tempting
to speculate that the exon 1 polymorphism could identify
a subgroup of patients who might benefit from a different
therapeutic approach. In view of the selective B2 antago-
nists that are now available, patients with a higher tran-
scription rate of the B2 receptor gene, namely carriers of
the 2G allele, may form a promising target for the clinical
use of these new drugs.
In summary, we have found a weak association be-
tween late-onset pediatric asthma and the exon 1 allele
BE1-2G of the B2 bradykinin receptor gene. Because pe-
diatric asthma is a complex disease with a polygenetic
background and strong environmental influences, large
or appropriately stratified cohorts will be needed to con-
firm and specify this association.
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